Epithelial Ovarian Cancer Drug Pipeline Analysis Report 2025

Epithelial ovarian cancer is a malignant tumor that arises from the epithelial cells lining the ovary. It is the most common type of ovarian malignancy, accounting for 85% to 90% of cases, primarily affecting women aged 40 and older. There is a significant clinical need for advanced therapies, as current treatment options have limitations. The growing focus on immunotherapy and targeted therapies will drive the advancements in epithelial ovarian cancer therapeutics. With ongoing research and innovation, the market for epithelial ovarian cancer treatment is expected to witness significant growth, improving treatment outcomes in the coming years.

Report Coverage

The Epithelial Ovarian Cancer Drug Pipeline Insight Report by the publisher gives comprehensive insights into epithelial ovarian cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for epithelial ovarian cancer. The epithelial ovarian cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The epithelial ovarian cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with epithelial ovarian cancer treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to epithelial ovarian cancer.

Epithelial Ovarian Cancer Drug Pipeline Outlook

Epithelial ovarian cancer is the most common type of ovarian cancer, originating in the epithelial cells lining the ovaries. It occurs due to genetic mutations that lead to uncontrolled cell growth, often linked to factors such as aging, family history, and hormonal influences. The disease typically remains asymptomatic in early stages, making early detection challenging.

Epithelial ovarian cancer is treated through a combination of surgery and chemotherapy. Surgery involves tumor removal, often including the ovaries, fallopian tubes, and uterus. Chemotherapy, using platinum-based drugs like carboplatin and paclitaxel, targets residual cancer cells. Individual treatment plans are based on cancer stage, genetic factors, and patient health conditions.

Epithelial Ovarian Cancer Epidemiology

Epithelial ovarian cancer accounts for 85%-90% of ovarian malignancies, primarily affecting women over 40 years. In 2022, the United States reported over 19,000 new cases and 12,000 deaths. The United Kingdom records around 7,400 cases annually, with incidence expected to rise by 15% by 2035. In India, it ranks third among female cancers, with 47,333 cases and 32,978 deaths in 2022.

Epithelial Ovarian Cancer - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of epithelial ovarian cancer drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Monoclonal Antibodies
• Small Molecules
• Gene Therapies
• Peptides
• Cell Therapies

By Route of Administration

• Oral
• Parenteral
• Others

Epithelial Ovarian Cancer - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total epithelial ovarian cancer clinical trials.

Epithelial Ovarian Cancer - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the epithelial ovarian cancer pipeline analysis include monoclonal antibodies, small molecules, gene therapies, peptides, and cell therapies. The epithelial ovarian cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for epithelial ovarian cancer.

Epithelial Ovarian Cancer Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the epithelial ovarian cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed epithelial ovarian cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in epithelial ovarian cancer clinical trials:

• Hoffmann-La Roche
• Amino Up Co., Ltd.
• PhotonPharma, Inc.
• Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Arsenal Biosciences, Inc.
• Mereo BioPharma
• Kancera AB
• RemeGen Co., Ltd.
• TORL Biotherapeutics, LLC
• CanariaBio Inc.
• Sutro Biopharma, Inc.
• Bio-Thera Solutions

Epithelial Ovarian Cancer Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for epithelial ovarian cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of epithelial ovarian cancer drug candidates.

Drug: Bevacizumab

Avastin (bevacizumab) is currently undergoing a Phase IV clinical development, in which it is being evaluated in patients with advanced/metastatic epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study, sponsored by Hoffmann-La Roche, aims to assess the drug’s safety and efficacy in real-world clinical settings. Bevacizumab, an anti-angiogenic monoclonal antibody, inhibits VEGF, reducing tumor blood supply and growth.

Drug: SHR-A1921

SHR-A1921 is an investigational therapy sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. in a Phase III trial. This study evaluates its efficacy and safety in platinum-resistant recurrent epithelial ovarian cancer, comparing it to standard chemotherapy options - doxorubicin, paclitaxel, and topotecan. With an estimated enrollment of 440 patients, the results could advance future treatment approaches.

Drug: RC88

RC88 is an antibody-drug conjugate (ADC) targeting mesothelin (MSLN). RemeGen Co., Ltd. is sponsoring this Phase II trial to evaluate RC88 for platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The study aims to assess the drug’s efficacy, safety, and pharmacokinetics.

Reasons To Buy This Report

The Epithelial Ovarian Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for epithelial ovarian cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into epithelial ovarian cancer collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Epithelial Ovarian Cancer - Pipeline Insight Report

• Which companies/institutions are leading the epithelial ovarian cancer drug development?
• What is the efficacy and safety profile of epithelial ovarian cancer pipeline drugs?
• Which company is leading the epithelial ovarian cancer pipeline development activities?
• What is the current epithelial ovarian cancer commercial assessment?
• What are the opportunities and challenges present in the epithelial ovarian cancer drug pipeline landscape?
• What is the efficacy and safety profile of epithelial ovarian cancer pipeline drugs?
• Which company is conducting major trials for epithelial ovarian cancer drugs?
• Which companies/institutions are involved in epithelial ovarian cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in epithelial ovarian cancer?

This product will be delivered within 3-5 business days.